title: [Lipid profile of patients with increased risk for cardiovascular events in daily clinical practice].
abstract: Although there are specific guidelines regarding the treatment of dyslipidemia in highly risk patients, these recommendations are usually inadequately followed. The aim of this study is to investigate risk factors in patients with increased cardiovascular risk currently treated in Brazil and Venezuela. Medical charts of 412 patients were selected in 4 institutions. Patients were divided into groups according to the use of lipid-lowering drugs (LLD), particularly statins. Patients who did not use LLD showed higher levels of total cholesterol (p< 0.001), LDL cholesterol (p< 0,001) and HDL cholesterol (p< 0.001), besides lower levels of triglycerides (p< 0.001). The use of statins was associated with a decrease in levels of total cholesterol (from 251.0 +/- 40.0 to 196.0 +/- 46.0), LDL cholesterol (from 168.0 +/- 36.0 to 116.0 +/- 39.0), HDL cholesterol (from 51.0 +/- 46.0 to 46.0 +/- 12.0) and triglycerides (from 181.0 +/- 120.0 to 160.0 +/-79.0). Finally, only a small percentage of patients, even those under treatment with LLD, showed cholesterol levels according to currently available guidelines. Therefore, although the guidelines for the treatment of dyslipidemia are widely known, only a small percentage of patients achieve adequate levels of cholesterol. It is necessary to decrease lipid levels of these patients by increasing the dose of the statins or using a second drug.
authors.affiliation: Instituto Estadual de Diabetes e Endocrinologia, Rio de Janeiro, RJ. rom_br@yahoo.com
authors.forename: Rodrigo O
authors.initials: RO
authors.lastname: Moreira
authors.forename: Raul D
authors.initials: RD
authors.lastname: Santos
authors.forename: Lilton
authors.initials: L
authors.lastname: Martinez
authors.forename: Fabiana C
authors.initials: FC
authors.lastname: Saldanha
authors.forename: Jara Lucia A C
authors.initials: JL
authors.lastname: Pimenta
authors.forename: Josefina
authors.initials: J
authors.lastname: Feijoo
authors.forename: Natalie
authors.initials: N
authors.lastname: Jahnke
authors.forename: Otávio C
authors.initials: OC
authors.lastname: Mangile
authors.forename: Rosane
authors.initials: R
authors.lastname: Kupfer
mesh_terms: D015992:Body Mass Index; D001938:Brazil; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000209:etiology*; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000378:metabolism; D006949:Hyperlipidemias / Q000188:drug therapy / Q000378:metabolism*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D008297:Male; D012189:Retrospective Studies; D012307:Risk Factors; D014687:Venezuela
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008055:Lipids; D002784:Cholesterol